Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome

Internal Medicine

Volumn 46, Issue 17, 2007, Pages 1331-1336

  Ichikawa, Yoshihiko ^a  

^a Otaru Municipal Second Hospital   (Japan)

Author keywords

Angiotensin II; Hypertension; Insulin resistance

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPID; ORAL ANTIDIABETIC AGENT; TELMISARTAN; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; MIDDLE AGED;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 34548731369     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.7173     Document Type: Article

References (21)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
2. Definition and the diagnostic standard for metabolic syndrome - Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Nippon Naika Gakkai Zasshi 94: 794-809, 2005 (in Japanese Abstract in Japanese).
3. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 27: 247-255, 2004.
4. Kurtz TW Pravenec M. Antidiabetic mechanisms of angiotensinconverting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 22: 2253-2261,2004.
5. Benson SC, Pershadsingh HA, Ho Cl, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 993-1002, 2004.
6. Nagel JM, Tietz AB, Goke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 55: 1149-1154, 2006.
7. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40: 609-611, 2002.
8. Jordan J, Engeh S, Boschmann M, et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens 23: 2313-2318, 2005.
9. Fogari R, Derosa G, Zoppi A, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 28: 209-214, 2005.
10. Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 92: 3J9J, 2003.
11. Picard F, Auwerx J. PPAR (gamma) and glucose homeostasis. Annu Rev Nutr 22: 167-197, 2002.
12. Fujimoto M, Masuzaki H, Tanaka T, et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 576: 492-497, 2004.
13. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartqn but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47: 1003-1009, 2006.
14. Wienen W, Entzeroth M, Van Meel J. A review on Telmisartan: a novel, long acting angiotensin 11 receptor antagonist. Cardiovasc Drug Rev 18: 127-156, 2000.
15. Furukawa S, Fujita T, Shimabukuro, M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761, 2004.
16. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
17. Guzik TJ, Mangalat D, Korbut R. Adipocytoldnes - novel link between inflammation and vascular function? I Physiol Pharmacol 57: 505-528, 2006.
18. Derosa G, Cicero A, D'Angelo A. Telmisartan and Irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: Effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 29: 849-856, 2006.
19. Hoffmann IS, Cubeddu LX Increased blood pressure reactivity to dietary salt in patients with the metabolic syndrome. J Hum Hypertens 2007.
20. Anderssen SA, Carroll S, Urdal P, Hohne 1. Combined diet and exercise intervention reverses the metabolic syndrome in middle-aged males: results from the Oslo Diet and Exercise Study. Scand J Med Sci Sports 2007.
21. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42: 76-81, 2003.